关于在炎症性疾病中阻断白介素-6受体和白介素-6的共识声明:更新版
本文是对既往关于白介素-6(IL-6)通路抑制剂医学使用的共识文件的更新,基于最新证据和专家意见。通过系统性文献检索并由国际专家和患者参与共识过程,覆盖类风湿关节炎、幼年特发性关节炎、巨细胞动脉炎、大动脉炎、成人Still病、Castleman病、CAR-T细胞诱导的细胞因子释放综合征、视神经脊髓炎谱系疾病和重型COVID-19等适应证的剂量与人群,以及治疗前筛查、安全性、禁忌证和监测。
要点
- 共识覆盖IL-6通路抑制剂在全球获批的多种炎症性适应证的剂量与人群。
- 共识还涉及治疗前筛查、安全性、禁忌证和监测等临床方面。
- 本文件为医疗专业人员、患者、管理者和支付方提供综合共识信息。
核心结论
- 文件提供了关于使用IL-6抑制治疗炎症性疾病的综合共识,以告知医疗专业人员(包括研究者)、患者、管理者和支付方。
研究设计与样本
- 进行了聚焦于炎症性疾病中IL-6通路抑制剂的系统性文献检索,随后由大型国际专家和患者团体参与共识过程,所有参与者参与制定共识声明和准备本文件。
主要发现
- 共识过程覆盖了全球获批的IL-6通路抑制剂不同适应证的剂量和人群相关方面。
- 涵盖的适应证包括类风湿关节炎、多关节型和全身型幼年特发性关节炎、巨细胞动脉炎、大动脉炎、成人Still病、Castleman病、嵌合抗原受体T细胞诱导的细胞因子释放综合征、视神经脊髓炎谱系疾病和重型COVID-19。
- 还涉及IL-6通路抑制剂使用的其他临床方面,包括治疗前筛查、安全性、禁忌证和监测。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Targeting interleukin (IL)-6 has become a major therapeutic strategy in the treatment of immune-mediated inflammatory disease. Interference with the IL-6 pathway can be directed at the specific receptor using anti-IL-6Rα antibodies or by directly inhibiting the IL-6 cytokine. This paper is an update of a previous consensus document, based on most recent evidence and expert opinion, that aims to inform on the medical use of interfering with the IL-6 pathway. METHODS: A systematic literature research was performed that focused on IL-6-pathway inhibitors in inflammatory diseases. Evidence was put in context by a large group of international experts and patients in a subsequent consensus process. All were involved in formulating the consensus statements, and in the preparation of this document. RESULTS: The consensus process covered relevant aspects of dosing and populations for different indications of IL-6 pathway inhibitors that are approved across the world, including rheumatoid arthritis, polyarticular-course and systemic juvenile idiopathic arthritis, giant cell arteritis, Takayasu arteritis, adult-onset Still's disease, Castleman's disease, chimeric antigen receptor-T-cell-induced cytokine release syndrome, neuromyelitis optica spectrum disorder and severe COVID-19. Also addressed were other clinical aspects of the use of IL-6 pathway inhibitors, including pretreatment screening, safety, contraindications and monitoring. CONCLUSIONS: The document provides a comprehensive consensus on the use of IL-6 inhibition to treat inflammatory disorders to inform healthcare professionals (including researchers), patients, administrators and payers.
引用
- Aletaha D, Kerschbaumer A, Kastrati K, et al. Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update. Ann Rheum Dis. 2022. PMID: 35953263. doi:10.1136/ard-2022-222784
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。